Literature DB >> 9342363

Prevention of development of autoimmune disease in BXSB mice by mixed bone marrow transplantation.

B Y Wang1, N S El-Badri, R A Good.   

Abstract

Transplantations of fully allogeneic, autoimmune-resistant T-cell-depleted marrow (TCDM) plus syngeneic, autoimmune-prone TCDM into lethally irradiated BXSB mice were carried out to investigate the ability of the mixed bone marrow transplantation (BMT) to prevent development of autoimmune disease and, at the same time, to reconstitute fully the immunity functions of heavily irradiated BXSB recipients. Male BXSB mice were engrafted with mixed TCDM from both allogeneic, autoimmune-resistant BALB/c mice and syngeneic, autoimmune-prone BXSB mice. BMT with mixed TCDM from both resistant and susceptible strains of mice (mixed BMT) prolonged the median life span and inhibited development of glomerulonephritis in BXSB mice. BMT with mixed TCDM also prevented the formation of anti-DNA antibodies that is typically observed in male mice of this strain. Moreover, mixed BMT reconstituted primary antibody production in BXSB recipients, so that no annoying immunodeficiencies that are regularly observed in fully allogeneic chimeras were present in the recipient of the mixed TCDM. These findings indicate that transplanting allogeneic, autoimmune-resistant TCDM plus syngeneic, autoimmune-prone TCDM into lethally irradiated BXSB mice prevents development of autoimmune disease in this strain of mice. In addition, this dual BMT reconstitutes the immunity functions and avoids the immunodeficiencies that occur regularly in fully allogeneic chimeras after total-body irradiation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9342363      PMCID: PMC23703          DOI: 10.1073/pnas.94.22.12065

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  14 in total

1.  Organ-specific and systemic autoimmune diseases originate from defects in hematopoietic stem cells.

Authors:  S Ikehara; M Kawamura; F Takao; M Inaba; R Yasumizu; S Than; H Hisha; K Sugiura; Y Koide; T O Yoshida
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

Review 2.  A comparative immunologic analysis of several murine strains with autoimmune manifestations.

Authors:  A N Theofilopoulos; P J McConahey; S Izui; R A Eisenberg; A B Pereira; W D Creighton
Journal:  Clin Immunol Immunopathol       Date:  1980-03

3.  Abnormal stem cells in autoimmune-prone mice are responsible for premature thymic involution.

Authors:  T Nakamura; S Ikehara; R A Good; S Inoe; K Sekita; F Furukawa; H Tanaka; M M Oo; Y Hamashima
Journal:  Thymus       Date:  1985

4.  Prevention and induction of occlusive coronary vascular disease in autoimmune (W/B)F1 mice by haploidentical bone marrow transplantation: possible role for anticardiolipin autoantibodies.

Authors:  H Mizutani; R W Engelman; K Kinjoh; Y Kurata; S Ikehara; R A Good
Journal:  Blood       Date:  1993-11-15       Impact factor: 22.113

5.  Development and characterization of monoclonal antiplatelet autoantibodies from autoimmune thrombocytopenic purpura-prone (NZW x BXSB)F1 mice.

Authors:  H Mizutani; R W Engelman; Y Kurata; S Ikehara; R A Good
Journal:  Blood       Date:  1993-08-01       Impact factor: 22.113

6.  Monoclonal human anti-DNA antibodies from EB virus-transformed lymphocytes of systemic lupus erythematosus (SLE) patients.

Authors:  T Sasaki; T Muryoi; Y Sekiguchi; E Tamate; K Yoshinaga; Y Kitagawa
Journal:  J Clin Immunol       Date:  1985-07       Impact factor: 8.317

7.  Induction of immunological tolerance in full major and multiminor histocompatibility-disparate mice using a mixed bone marrow transplantation model.

Authors:  N S el Badri; R A Good
Journal:  Proc Soc Exp Biol Med       Date:  1994-01

8.  Anti-bacterial immunity to Listeria monocytogenes in allogeneic bone marrow chimera in mice.

Authors:  K Onoé; R A Good; K Yamamoto
Journal:  J Immunol       Date:  1986-06-01       Impact factor: 5.422

9.  Lymphohemopoietic reconstitution using wheat germ agglutinin-positive hemopoietic stem cell transplantation within but not across the major histocompatibility antigen barriers.

Authors:  N S el Badri; R A Good
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

10.  Humoral and cell-mediated immune responses in fully allogeneic bone marrow chimera in mice.

Authors:  K Onoé; G Fernandes; R A Good
Journal:  J Exp Med       Date:  1980-01-01       Impact factor: 14.307

View more
  6 in total

1.  Nonmyeloablative allogeneic bone marrow transplantation of a child with systemic autoimmune disease and lung vasculitis.

Authors:  Olcay Y Jones; Richard A Cahill
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

2.  Effective treatment of autoimmune disease and progressive renal disease by mixed bone-marrow transplantation that establishes a stable mixed chimerism in BXSB recipient mice.

Authors:  B Wang; Y Yamamoto; N S El-Badri; R A Good
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

3.  Autoimmune disease: is it a disorder of the microenvironment?

Authors:  Nagwa S El-Badri; Amal Hakki; Annabella Ferrari; Rania Shamekh; Robert A Good
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 4.  Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure?

Authors:  Richard K Burt; Shimon Slavin; William H Burns; Alberto M Marmont
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.319

5.  The hematopoietic compartment is sufficient for lupus development resulting from the POLB-Y265C mutation.

Authors:  Tania Rahim; Madison A Levinson; Kelly E W Carufe; Matthew Burak; Rithy Meas; Stephen Maher; Alfred L M Bothwell; Naomi Gades; Joann B Sweasy
Journal:  PLoS One       Date:  2022-04-29       Impact factor: 3.240

6.  Tolerization of anti-Galalpha1-3Gal natural antibody-forming B cells by induction of mixed chimerism.

Authors:  Y G Yang; E deGoma; H Ohdan; J L Bracy; Y Xu; J Iacomini; A D Thall; M Sykes
Journal:  J Exp Med       Date:  1998-04-20       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.